Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Lisaftoclax in Diffuse large B-cell lymphoma refractory: NCT07255963 Clinical Landscape Report 2026
18 September 2026
NCT07255963 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Eribulin mesylate in Triple Negative Breast Cancer: NCT07255612 Clinical Landscape Report 2026
18 September 2026
NCT07255612 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BAFF-R Chimeric Antigen Receptor T(Hebei Taihe Chunyu Biotechnology) in Mantle-Cell Lymphoma: NCT07259070 Clinical Landscape Report 2026
18 September 2026
NCT07259070 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tagitanlimab in PD-L1 positive Triple Negative Breast Cancer: NCT07258108 Clinical Landscape Report 2026
18 September 2026
NCT07258108 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Toripalimab in Triple Negative Breast Cancer: NCT07256964 Clinical Landscape Report 2026
18 September 2026
NCT07256964 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[68Ga]Ga-NNS309 in Pancreatic Ductal Adenocarcinoma: NCT07261631 Clinical Landscape Report 2026](https://synapse-static.patsnap.com/strapi-static/Blog_cover_04_d2b0c3c766.jpg)
9 min read
[68Ga]Ga-NNS309 in Pancreatic Ductal Adenocarcinoma: NCT07261631 Clinical Landscape Report 2026
18 September 2026
NCT07261631 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Azacitidine in Triple Negative Breast Cancer: CTRI/2025/12/098327 Clinical Landscape Report 2026
18 September 2026
CTRI/2025/12/098327 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
KSV-01 in Diffuse large B-cell lymphoma recurrent: NCT07260812 Clinical Landscape Report 2026
18 September 2026
NCT07260812 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Golcadomide Hydrochloride in Diffuse large B-cell lymphoma recurrent: NCT07269639 Clinical Landscape Report 2026
18 September 2026
NCT07269639 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Pembrolizumab in Node-positive breast cancer: NCT07276880 Clinical Landscape Report 2026
18 September 2026
NCT07276880 clinical landscape for Node-positive breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nogapendekin alfa inbakicept-pmln in Synovial Sarcoma: NCT07261657 Clinical Landscape Report 2026
18 September 2026
NCT07261657 clinical landscape for Synovial Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LNTH-2403 in Solid tumor: NCT07272642 Clinical Landscape Report 2026
18 September 2026
NCT07272642 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.